Description: C3b/iC3b/C3c, Mouse, mAb 2/11, immuno assay antibody
The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported.
Proteolysis by certain enzymes results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b, C3c, C3dg and C3f. The monoclonal antibody 2/11 is specific for cleaved C3 fragments C3b, iC3b, and C3c, and for activated C3. Therefore, positive reactivity in tissues is associated with activation of he complement cascade and C3 cleavage. In case of an acute inflammatory reaction lots of C3 are processed into the products recognized by 2/11 and is as such useful as marker for inflammatory reaction. In chronic inflammatory conditions minimal reactivity with 2/11 may observed. In such cases primarily the C3dg product resides at the place of inflammation (C3c being cleared) which is not recognized by antibody 2/11. The chronic processing/activation of C3 is taking place at a lower level, which would reduce detection of the C3 fragments C3b, iC3b, and C3c.
Next to detection of C3 fragments C3b, iC3b, and C3c, the monoclonal antibody 2/11 inhibits the hemolytic activity of mouse complement in a dose-dependent manner.
|Product type||Monoclonal antibodies|
|Formulation||0.5 mg of 0.2 μm filtered protein G purified antibody solution in PBS with a concentration of at least 0.5 mg/ml (exact concentration is indicated on the label).|
|Application||F, FC, FS, IA, IF, W|
|Application Notes||F: Fixation of sections in acetone for 5‘, pretreatment with 3% hydrogen peroxide in methanol at RT to quench endogenous peroxidases. As negative control, sections from C3-deficient mice were used. (Ref.1)
FC: Mouse splenocytes were incubated with autologous, freshly drawn mouse serum to fix the C3 fragments before staining. As negative control splenocytes of C3 deficient mice was used. Antibody 2/11stains the neoantigenic site on the C3 activation fragments. (Ref.1)
FS: Antibody 2/11 inhibits hemolysis in a dose-dependent manner. (Ref.1)
W: A non-reduced sample treatment and SDS-PAGE was used. The band size is 150 kDa (Ref.1).
IA: Supernatant of antibody 2/11 was incubated on anti-rat IgG Fc coated plates. After incubation with sample, HRP-conjugated polyclonal goat anti-mouse C3 was used for detection. (Ref.1)
|Use||Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.|
|Positive Control||Mouse splenocytes preincubated with serum from the same animal.|
|Negative Control||C3-deficient mouse cells.|
|References||1. Mastellos, D et al; Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol 2004, 40: 1213
2. Markiewski, M et al; C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 2004, 173: 747
3. Markiewski, M et al; Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9: 1225
|Storage and stability||Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.|
|Precautions||For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use of or derivation of this product.|
|Disease||Infectious diseases, Nephrology|